Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03548415 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands
A Phase 2 study, sponsored by Ionis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT03548415 is a Phase 2 study that has completed, run by Ionis Pharmaceuticals. The registered enrollment target is 43 participants.
The verdict
NCT03548415, a Phase 2 study, has completed, sponsored by Ionis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
The purpose of this study was to assess the safety, tolerability, and efficacy of IONIS-GHR-LRx in up to 60 participants with acromegaly.
Interventions
- DRUG Placebo
- DRUG IONIS-GHR-LRx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2018-09-13 |
| Est. Completion | 2021-04-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03548415
The ClinicalTrials.gov registry entry for NCT03548415 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ionis Pharmaceuticals, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03548415 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03548415 about?
NCT03548415 is a clinical study titled "Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands". The purpose of this study was to assess the safety, tolerability, and efficacy of IONIS-GHR-LRx in up to 60 participants with acromegaly.
What is the current status of trial NCT03548415?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2018-09-13. Estimated completion is 2021-04-02.
What interventions are being tested in trial NCT03548415?
The interventions under investigation include: Placebo (DRUG), IONIS-GHR-LRx (DRUG).
Who is sponsoring clinical trial NCT03548415?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.